Bangladesh pharmaceutical market in 2011 stood at approximately US $ 800 million‚ which is very small when compared to the population base of the country‚ which currently stands at about 140 million. To put this number on a proper perspective‚ the total global pharmaceutical sale in 2011 was $600 billion. This is expected to grow about $730 billion in 2013. Of course the majority of the sale in 2011 was in brand products‚ the market segment where Bangladesh does not or is not expected to participate
Premium Inflation Central Intelligence Agency Economic growth
Merck and Co. and river blindness MANUEL VELASQUEZ‚ Business Ethics. Concepts and cases 4th edt.‚ Prentice Hall‚ Upper Saddle River‚ New Jersey‚ 1998 River blindness is an agonizing disease that affects some 18 million impoverished people living in remote villages along the banks of rivers in tropical regions of Africa and Latin America. The disease is caused by a tiny parasitic worm that is passed from person to person by the bite of the black fly which breeds in river waters. The tiny worms
Premium Pharmaceutical industry Ethics Drug discovery
c. Moody’s Investors Service downgraded the long-term senior unsecured rating of AZN from A1 to Aa2 in 2007. Assess any potential association between this downgrade and AZN’s arrangements with Merck. Paris‚ July 30‚ 2007 -- Moody’s Investors Service downgraded the long-term senior unsecured ratings of AstraZeneca plc and its guaranteed subsidiary to A1 from Aa2. This downgrade followed the announcement of AstraZeneca’s acquisition of MedImmune for a total consideration of more than US$15 billion
Premium Money
The management of Cooper Industries‚ Inc.‚ is considering whether to acquire the Nicholson File Company‚ a leading manufacturer of hand tools. The Nicholson family and other members of the management group own about 20% of the Nicholson stock; the remainder is publicly held. From the standpoint of Cooper‚ an affirmative decision may involve Cooper in a bidding contest with two other companies‚ which have already purchased part of the outstanding Nicholson stock and made tender offers in an effort
Premium Cash flow Stock Income statement
TRAPHACO JOIN STOCK COMPANY (TRA) DOMESCO MEDICAL IMPORT-EXPORT JOIN STOCK COMPANY (DMC) HAUGIANG PHARMACEUTICAL JOIN STOCK COMPANY (DHG) IMEXPHARM PHARMACEUTICAL JOIN STOCK COMPANY (IMP) gROUP PHARMACEUTICAL: truong quang khoa huynh minh tri Cao huynh ngoc khanh huynh le phuong thao ngo thi ngoc anh to ha cat anh Contents 1 INTRODUCTION 1.1 INDUSTRIAL OVERVIEW Pharmaceutical industry is an important sector in the national economy‚ the production of functional medicine service
Premium Generally Accepted Accounting Principles Asset Balance sheet
The Pharmaceutical Industry: Key success factors High profit after launching the product: Before a pharmaceutical company establishes a new product it takes them a lot time and work. The whole project‚ from the beginning until the end‚ where the medicine can be launched can last about 12 years. But once the drug is on marked the producing company has very high margins. On average‚ a Blockbuster drug is for about eight years on the marked and each year it has revenues in the range of one
Premium Pharmacology Medicine Pharmaceutical drug
Pharmaceutical Industry - Key Success Factors There’s a time for everything. For Dr Ramakanta Panda‚ it was time to build a ’modern hospital’ in India. As a cardiac surgeon from the prestigious Cleveland Clinic‚ US‚ he was known for his super-safe hands. But his ideas proved too radical for the design team. Whoever heard of picture windows to ward off ICU psychosis? Or counselling areas for patients’ relatives? How would cafeteria‚ convenience store‚ library‚ public booth‚ Internet access‚ and
Premium Health care Patient Health care provider
Merck was at the top of the pharmaceutical market for many years. The company made substantial profits almost every year. Not only were they a company that made money but they also made their financial gains in an ethical manor. Fourton magazine even named them the “most admired” company. But in 2004‚ the company would be faced with major challenges that would threaten to end the company’s existence. Their once best selling painkiller Viol had been recalled by the federal government because the drug
Premium Pharmacology Pharmaceutical industry
evidence. A number of contributions setting the ground for future empirical research are provided. 1 1. Introduction The importance of the resource-based view (RBV) of strategic management is manifest in its rapid diffusion throughout the strategy literature (e.g.‚ Wernerfelt‚ 1984; Rumelt‚ 1984; Barney‚ 1986‚ 1991; Dierickx & Cool‚ 1989; Mahoney & Pandian‚ 1992; Amit & Schoemaker‚ 1993; Peteraf‚ 1993; Maijoor & Witteloostuijn‚ 1996). Drawing on previous research in RBV‚ this study aims
Premium Management Strategic management Innovation
Question 1) Why was McNeil’s new product proposal rejected? Should it have been? Explain. McNeils’ proposal was rejected because it did not meet the target return 15%‚ which was decided by Hubbard. However‚ the EVA is unfavorable under 15% return. Hubbard also states that a company like Enager should have a 12% return on EBIT. With this being said‚ McNeil’s proposal demonstrates a return of 13% (ROA = EBIT/Assets = $390‚000/$3‚000‚000)‚ and a favorable EVA will be provided under this return figure
Premium Scientific method Mind Philosophy